|(6R,7R)-7-((R)-2-(4-乙基-2,3-二氧代哌嗪-1-甲酰胺基)-2-(4-羟基苯基)乙酰胺基)-3-(((1-甲基-1H-四唑-5-基)硫基)甲基)-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛烷-2-烯-2-羧酸|CsnPharm

CAS No.: 62893-19-0

Cefoperazone/头孢哌酮 Catalog No. CSN10575

Synonyms: Cefobid;Cefozon;T-1551

Cefoperazone is a third-generation β-lactam cephalosporin antibiotic which can bind to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Cefoperazone is a third‐generation cephalosporin and is one of a small number of cephalosporins that are effective in treating Pseudomonas bacterial infections (MIC50 25 μg/mL). The hydrolysis product of cefoperazone was noncovalently bound in the active site of PBP3. This may be important in the design of new noncovalent PBP3 inhibitors^[3]. After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was 111 microgram/ml at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4 microgram/ml. Cefoperazone was 90% bound to serum proteins^[4]. Both the inhibitory potency of the cephalosporins for Mrp2-mediated (multidrug resistance-associated protein) transport and the uptake of cephalosporins by Mrp2-expressing vesicles were molecular weight-dependent^[5].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... more >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD Collapse <<
NCT03003273	Neutropenia, Febrile ... more >> Pediatric Cancer Collapse <<	Phase 3	Recruiting	December 2018	India ... more >> Department of Medical Oncology, AIIMS Recruiting New Delhi, India, 110029 Contact: Sameer Bakhshi, MD 011-29575237 sambakh@hotmail.com Collapse <<
NCT01601093	Respiratory Tract Infections ... more >> Urinary Tract Infections Collapse <<	Phase 2	Unknown	November 2013	China, Jiangsu ... more >> the First Affiliated Hospital With Medical University Recruiting Nanjing, Jiangsu, China Contact: hong wh wang, doctor 025-83714511 ext 6360 Sub-Investigator: mao hm huang, doctor Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.5488 mL
- 7.7439 mL
- 15.4879 mL
- 5 mM
- 0.3098 mL
- 1.5488 mL
- 3.0976 mL
- 10 mM
- 0.1549 mL
- 0.7744 mL
- 1.5488 mL

技术信息

CAS号

62893-19-0

储存条件

粉末: Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C25H27N9O8S2

运输

蓝冰

分子量

645.67

别名

Cefobid;Cefozon;T-1551;C-06883;C 06883 D07645;D-07645;头孢哌酮

溶解度

DMSO	400.0 mg/mL (619.5 mM) warming
Water	insoluble

动物实验配方

IP	2% DMSO+2% Tween80+30% PEG300+water	8 mg/mL	clear
PO	0.5% CMC-Na	54 mg/mL	suspension

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... more >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD Collapse <<
NCT03003273	Neutropenia, Febrile ... more >> Pediatric Cancer Collapse <<	Phase 3	Recruiting	December 2018	India ... more >> Department of Medical Oncology, AIIMS Recruiting New Delhi, India, 110029 Contact: Sameer Bakhshi, MD 011-29575237 sambakh@hotmail.com Collapse <<
NCT01601093	Respiratory Tract Infections ... more >> Urinary Tract Infections Collapse <<	Phase 2	Unknown	November 2013	China, Jiangsu ... more >> the First Affiliated Hospital With Medical University Recruiting Nanjing, Jiangsu, China Contact: hong wh wang, doctor 025-83714511 ext 6360 Sub-Investigator: mao hm huang, doctor Collapse <<
NCT03436719	Rectal Cancer	Not Applicable	Recruiting	August 31, 2020	Russian Federation ... more >> State Scientific Centre of Coloproctology Recruiting Moscow, Russian Federation, 123423 Collapse <<
NCT01280461	-	-	Unknown	December 2011	Taiwan ... more >> Taipei Medical University - WanFang Hospital Taipei, Taiwan Collapse <<
NCT02060149	Pneumonia	Phase 1 Phase 2	Unknown	April 2015	China, Shaanxi ... more >> Xijing Hospital Not yet recruiting Xi'an, Shaanxi, China, 710032 Contact: zhikui li, doctor 13571855922 lizhikui@fmmu.edu.cn Collapse <<
NCT00463762	-	-	Withdrawn	-	-
NCT03776409	-	-	Not yet recruiting	December 1, 2019	China, Shaanxi ... more >> First Affiliated Hospital of Xian Jiaotong University Not yet recruiting Xi'an, Shaanxi, China, 710061 Contact: Yalin Dong, Ph.D Collapse <<
NCT01992198	Pancreatitis,Acute Necrotizing	Phase 4	Unknown	December 2016	China, Shanghai ... more >> Depatrment of EICU,Ruijin Hospital Recruiting Shanghai, Shanghai, China, 200025 Contact: Erzhen Chen, M.D 86-13901753478 Contact: Enqiang , Mao 86-13501747906 Sub-Investigator: Zhitao Yang, M.D Collapse <<
NCT00360607	Infection	Phase 4	Completed	-	India ... more >> Pfizer Investigational Site Ahmedabad, Gujarat, India, 380 009 Pfizer Investigational Site Ahmedabad, Gujarat, India, 380 052 Pfizer Investigational Site Ahmedabad, Gujarat, India, 380016 Pfizer Investigational Site Bangalore, Karnataka, India, 560 001 Pfizer Investigational Site Kochi, Kerala, India, 682 026 Pfizer Investigational Site Kochi, Kerala, India, 682304 Pfizer Investigational Site Bhopal, Madhya Pradesh, India, 462 038 Pfizer Investigational Site Indore, Madhya Pradesh, India, 452 014 Pfizer Investigational Site Mumbai, Maharashtra, India, 400 022 Pfizer Investigational Site Pune, Maharashtra, India, 411 001 Pfizer Investigational Site Jaipur, Rajasthan, India, 302015 Pfizer Investigational Site Lucknow, Uttar Pradesh, India, 226 014 Pfizer Investigational Site Bangalore, India, 560 054 Pfizer Investigational Site Chandigarh, India, 160 012 Pfizer Investigational Site Coimbatore, India, 641 014 Pfizer Investigational Site Hyderabad, India, 500 068 Pfizer Investigational Site Hyderabad, India Pfizer Investigational Site Lucknow, India, 226 003 Pfizer Investigational Site Ludhiana, India, 141 001 Pfizer Investigational Site Mumbai, India, 400 012 Collapse <<

Cefoperazone/头孢哌酮 Catalog No. CSN10575

靶点选择性

请登录您的专属账户

确认信息